Centre for Addiction and Mental Health (CAMH)

Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) has inked a second supply deal with Canada-based Centre for Addiction and Mental Health (CAMH) concerning its botanical...

Mental health and addiction teaching hospital and research center CAMH has recently been awarded Canada's first federal grant by the Canadian Institutes of Health Research (CIHR) to study psilocybin for treatment-resistant depression.  The Centre for Addiction and Mental Health (CAMH)...